New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary

Abstract

Introduction:

To estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated.

Objectives and methods:

This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of disability, from the societal perspective, in HUF 2015.

Results:

A total of 521 patients (mean age 47 years) participated; 85% were below retirement age, and of these, 47% were employed. Employment was related to disability and MS affected productivity at work for 82% of those working. Overall, 94% and 66% of patients experienced fatigue and cognitive difficulties as a problem, respectively. The mean utility and annual costs were 0.691 and 3,432,000HUF at Expanded Disability Status Scale (EDSS) 0–3, 0.491 and 5,262,000HUF at EDSS 4–6.5 and 0.076 and 6,235,000HUF at EDSS 7–9, respectively. The average cost of a relapse was estimated at 240,500HUF.

Conclusion:

This study illustrates the burden of MS on Hungarian patients and provides current data that are important for the development of health policies.

Keywords

Multiple sclerosis burden of illness fatigue cognition costs HRQoL Hungary

Get full access to this article

View all access options for this article.

References

Gulacsi

Rotar

Niewada

. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ 2014; 15(suppl. 1): S13–S25.

Gustavsson

Svensson

Jacobi

. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 718–779.

Kobelt

Kasteng

. Access to innovative treatments for multiple sclerosis in Europe, 2009, http://www.comparatorreports.se/Access%20to%20MS%20treatments%20-%20October%202009.pdf

Pentek

Gulacsi

Rozsa

. Health status and costs of ambulatory patients with multiple sclerosis in Hungary. Ideggyogy Sz 2012; 65: 316–324.

Kovács

Nagy

Lang

. A sclerosis multiplex betgség közvetett egyéni és társadalmi terheinek felmérése Magyarországon. EGÉSZSÉG-GAZDASÁGTAN 2010; 5: 27–32.

McDonald

Compston

Edan

. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121–127.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

Pugliatti

Rosati

Carton

. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700–722.

Koch-Henriksen

Sorensen

. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520–532.

10.

Bencsik

Rajda

Fuvesi

. The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrad County, Hungary. Eur Neurol 2001; 46: 206–209.

11.

Zsiros

Fricska-Nagy

Fuvesi

. Prevalence of multiple sclerosis in Csongrad County, Hungary. Acta Neurol Scand 2014; 130: 277–282.

12.

Kobelt

Thompson

Berg

. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 2017; 23(8): 1123–1136.

13.

Kobelt

Berg

Lindgren

. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77: 918–926.

14.

Kobelt

Eriksson

Phillips

Berg

. The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms. Mult Scler 2017; 23(2S): 4–16.

15.

The EuroQol Group. EuroQol – A new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.

16.

Kobelt

Thompson

Berg

.; MSCOI Study Group and EMSP. New insights into the burden of multiple sclerosis. Mult Scler 2017; 23(8): 1123–1136.

17.

Dolan

Gudex

Kind

. The time trade-off method: Results from a general population study. Health Econ 1996; 5: 141–154.

18.

Debouverie

Laforest

Van Ganse

.; LORSEP Group. Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients. Mult Scler 2009; 15: 251–257.

19.

Hungarian Central Statistical Office, 2011, https://www.ksh.hu

20.

OECD. Average effective age of retirement versus the normal age in 2014 in OECD countries, http://www.oecd.org (2014, accessed 26 January 2017).

21.

Patwardhan

Matchar

Samsa

. Cost of multiple sclerosis by level of disability: A review of literature. Mult Scler 2005; 11: 232–239.

22.

Ernstsson

Gyllensten

Alexanderson

. Cost of illness of multiple sclerosis – A systematic review. PLoS ONE 2016; 11: e0159129.

23.

Fricska-Nagy

Fuvesi

Rozsa

. The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary. Mult Scler Relat Disord 2016; 7: 26–32.

24.

Sandi

Rudisch

Fuvesi

. The Hungarian validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery and the correlation of cognitive impairment with fatigue and quality of life. Mult Scler Relat Disord 2015; 4: 499–504.

25.

Gayou

Brochet

Dousset

. Transitional progressive multiple sclerosis: A clinical and imaging study. J Neurol Neurosurg Psychiatry 1997; 63: 396–398.